Short answer · Medically reviewed summary · Last updated: 2026-05-08
Hypoplastic Left Heart Syndrome (HLHS) is a rare congenital heart defect where the left side of the heart is underdeveloped, which was historically considered universally fatal until the development of surgical interventions in the 1980s. Today, understanding of Hypoplastic Left Heart Syndrome has evolved from a palliative-only approach to a complex, multi-stage reconstruction strategy that significantly improves survival rates and long-term quality of life. When was Hypoplastic Left Heart Syndrome first identified? The clinical entity now known as Hypoplastic Left Heart Syndrome was first formally described in the medical literature in 1952 by Dr.
1 people with Hypoplastic Left Heart Syndrome have shared their first-person experience on this question at DiseaseMaps.
Hypoplastic Left Heart Syndrome (HLHS) is a rare congenital heart defect where the left side of the heart is underdeveloped, which was historically considered universally fatal until the development of surgical interventions in the 1980s. Today, understanding of Hypoplastic Left Heart Syndrome has evolved from a palliative-only approach to a complex, multi-stage reconstruction strategy that significantly improves survival rates and long-term quality of life.
The clinical entity now known as Hypoplastic Left Heart Syndrome was first formally described in the medical literature in 1952 by Dr. Arnold Lev, who characterized the anatomical features of the underdeveloped left ventricle. Before this, infants born with Hypoplastic Left Heart Syndrome were often diagnosed simply with "cyanotic heart disease," as diagnostic imaging was nonexistent and surgical options were not yet viable.
For decades, a diagnosis of Hypoplastic Left Heart Syndrome was viewed as a terminal condition, with most infants passing away within the first two weeks of life. The landscape shifted dramatically in 1983 when Dr. William Norwood performed the first successful staged reconstruction, now known as the "Norwood procedure."
Modern genetics and prenatal imaging have transformed how we manage Hypoplastic Left Heart Syndrome. While the cause of Hypoplastic Left Heart Syndrome remains largely sporadic, current research into genetic markers is helping clinicians understand the recurrence risk for families. Furthermore, the 28 members of the DiseaseMaps community living with this condition represent the progress made in long-term survivorship, moving the focus from immediate survival to neurodevelopmental outcomes and lifelong cardiac care.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.